Ethyl 2-(butoxycarbonylamino)-5-phenylthiophene-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: Ethyl 2-(butoxycarbonylamino)-5-phenylthiophene-3-carboxylate
• 化学式: C₁₈H₂₁NO₄S
• mdl: MFCD02358144
• 分子量: 347.4
• InChiKey: DROKXAPMXVXZCA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  92.9
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• HETEROARYL HYDROXAMIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2776396A2

  公开（公告）日：2014-09-17
• PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2794616A1

  公开（公告）日：2014-10-29
• [EN] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE<br/>[FR] DÉRIVÉS DE PYRIMIDIN-4-ONE ET LEUR UTILISATION DANS LE TRAITEMENT, L'AMÉLIORATION OU LA PRÉVENTION D'UNE MALADIE VIRALE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013057253A1

  公开（公告）日：2013-04-25

  The present invention relates to a compound having the general formula (II), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, Formula (II) which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
• [EN] HETEROARYL HYDROXAMIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE<br/>[FR] DÉRIVÉS D'ACIDE HÉTÉROARYL-HYDROXAMIQUE ET LEUR UTILISATION POUR TRAITER, AMÉLIORER OU PRÉVENIR UNE MALADIE VIRALE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013057251A2

  公开（公告）日：2013-04-25

  The present invention relates to a compound having the general formula I, optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, enantiomer, or dsasiereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.